PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The miR-608 rs4919510 polymorphism may modify cancer susceptibility based on type.

Abstract Previous meta-analysis has not shown different effects of miR-608 rs4919510 polymorphism in specific cancer types and reported no significant association between rs4919510 and cancer risk among Chinese. However, more recent findings have been inconsistent. Therefore, we performed an updated meta-analysis to examine whether this polymorphism is associated with cancer risk based on ethnicity and type. A total of 18 case-control studies, comprising 12,517 cases and 15,624 controls, were included in our study. Surprisingly, in contrast with previous meta-analysis, a significant association between the rs4919510 polymorphism and cancer risk was observed in Chinese (CG vs CC: odds ratio = 1.11; 95% confidence interval = 1.04-1.19). In further stratified analyses based on cancer type, rs4919510 was significantly associated with an increased risk of papillary thyroid cancer (CG vs CC: odds ratio = 1.25; 95% confidence interval = 1.01-1.54) and exhibited borderline significant associations with increased risk of gastric cancer (GG vs CC: odds ratio = 1.27; 95% confidence interval = 1.00-1.62) and lung cancer (CG vs CC: odds ratio = 1.14; 95% confidence interval = 0.99-1.32), but a decreased risk of colorectal cancer (GG vs CC: odds ratio = 0.74; 95% confidence interval = 0.60-0.91). Moreover, the RegulomeDB database indicated that rs4919510 may affect the expression of two nearby genes ( SEMA4G and MRPL43), and the Cancer Genome Atlas database revealed that the expression level of SEMA4G was significantly lower in colorectal cancer and lung cancer tissues than that in adjacent non-tumour tissues, while the expression level of SEMA4G was significantly higher in gastric cancer tissues than that in adjacent non-tumour tissues. These findings provide evidence that the miR-608 rs4919510 polymorphism may modify cancer susceptibility in a type-specific manner. Furthermore, SEMA4G may function as an oncogene or tumour suppressor to regulate tumour development in a type-specific manner. Further studies with experimental evaluations are warranted.
PMID
Related Publications

MicroRNA-146a rs2910164 G/C polymorphism and gastrointestinal cancer susceptibility: a meta-analysis based on East Asian population.

Pri-Mir-34b/C and Tp-53 Polymorphisms are Associated With The Susceptibility of Papillary Thyroid Carcinoma: A Case-Control Study.

MiR-146a rs2910164 G/C polymorphism and gastric cancer susceptibility: a meta-analysis.

MiR-146a rs2910164 polymorphism increases risk of gastric cancer: a meta-analysis.

Association between polymorphisms in pre-miRNA genes and risk of lung cancer in a Chinese non-smoking female population.

Authors

Mayor MeshTerms

Genetic Association Studies

Genetic Predisposition to Disease

Keywords

MiR-608

cancer

polymorphism

rs4919510

the Cancer Genome Atlas

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28653886
OWN - NLM
STAT- MEDLINE
DA  - 20170627
DCOM- 20170711
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - The miR-608 rs4919510 polymorphism may modify cancer susceptibility based on
      type.
PG  - 1010428317703819
LID - 10.1177/1010428317703819 [doi]
AB  - Previous meta-analysis has not shown different effects of miR-608 rs4919510
      polymorphism in specific cancer types and reported no significant association
      between rs4919510 and cancer risk among Chinese. However, more recent findings
      have been inconsistent. Therefore, we performed an updated meta-analysis to
      examine whether this polymorphism is associated with cancer risk based on
      ethnicity and type. A total of 18 case-control studies, comprising 12,517 cases
      and 15,624 controls, were included in our study. Surprisingly, in contrast with
      previous meta-analysis, a significant association between the rs4919510
      polymorphism and cancer risk was observed in Chinese (CG vs CC: odds ratio =
      1.11; 95% confidence interval = 1.04-1.19). In further stratified analyses based 
      on cancer type, rs4919510 was significantly associated with an increased risk of 
      papillary thyroid cancer (CG vs CC: odds ratio = 1.25; 95% confidence interval = 
      1.01-1.54) and exhibited borderline significant associations with increased risk 
      of gastric cancer (GG vs CC: odds ratio = 1.27; 95% confidence interval =
      1.00-1.62) and lung cancer (CG vs CC: odds ratio = 1.14; 95% confidence interval 
      = 0.99-1.32), but a decreased risk of colorectal cancer (GG vs CC: odds ratio =
      0.74; 95% confidence interval = 0.60-0.91). Moreover, the RegulomeDB database
      indicated that rs4919510 may affect the expression of two nearby genes ( SEMA4G
      and MRPL43), and the Cancer Genome Atlas database revealed that the expression
      level of SEMA4G was significantly lower in colorectal cancer and lung cancer
      tissues than that in adjacent non-tumour tissues, while the expression level of
      SEMA4G was significantly higher in gastric cancer tissues than that in adjacent
      non-tumour tissues. These findings provide evidence that the miR-608 rs4919510
      polymorphism may modify cancer susceptibility in a type-specific manner.
      Furthermore, SEMA4G may function as an oncogene or tumour suppressor to regulate 
      tumour development in a type-specific manner. Further studies with experimental
      evaluations are warranted.
FAU - Wu, Shuangshuang
AU  - Wu S
AD  - 1 Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical
      University, Nanjing, China.
FAU - Yuan, Weiyan
AU  - Yuan W
AD  - 2 Department of Gastroenterology, Affiliated Hospital of Nantong University,
      Nantong, China.
FAU - Shen, Yu
AU  - Shen Y
AD  - 1 Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical
      University, Nanjing, China.
FAU - Lu, Xiao
AU  - Lu X
AD  - 3 Department of Oncology, Changshu No.1 People's Hospital, Changshu, China.
FAU - Li, Yue
AU  - Li Y
AD  - 1 Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical
      University, Nanjing, China.
FAU - Tian, Tian
AU  - Tian T
AD  - 4 Department of Epidemiology and Biostatistics, School of Public Health, Nantong 
      University, Nantong, China.
FAU - Jiang, Liying
AU  - Jiang L
AD  - 4 Department of Epidemiology and Biostatistics, School of Public Health, Nantong 
      University, Nantong, China.
FAU - Zhuang, Xun
AU  - Zhuang X
AD  - 4 Department of Epidemiology and Biostatistics, School of Public Health, Nantong 
      University, Nantong, China.
FAU - Wu, Jianqing
AU  - Wu J
AD  - 1 Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical
      University, Nanjing, China.
FAU - Chu, Minjie
AU  - Chu M
AD  - 4 Department of Epidemiology and Biostatistics, School of Public Health, Nantong 
      University, Nantong, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (MIRN608 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Mitochondrial Proteins)
RN  - 0 (Ribosomal Proteins)
RN  - 0 (Semaphorins)
RN  - 0 (mitochondrial ribosomal protein L44, human)
RN  - Thyroid cancer, papillary
SB  - IM
MH  - Asian Continental Ancestry Group
MH  - Carcinoma/genetics/pathology
MH  - Colorectal Neoplasms/genetics/pathology
MH  - Ethnic Groups
MH  - Gene Expression Regulation, Neoplastic
MH  - *Genetic Association Studies
MH  - *Genetic Predisposition to Disease
MH  - Genotype
MH  - Humans
MH  - Lung Neoplasms/genetics/pathology
MH  - MicroRNAs/*genetics
MH  - Mitochondrial Proteins/biosynthesis/genetics
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Ribosomal Proteins/biosynthesis/genetics
MH  - Risk Factors
MH  - Semaphorins/biosynthesis/*genetics
MH  - Stomach Neoplasms/genetics/pathology
MH  - Thyroid Neoplasms/genetics/pathology
OTO - NOTNLM
OT  - MiR-608
OT  - cancer
OT  - polymorphism
OT  - rs4919510
OT  - the Cancer Genome Atlas
EDAT- 2017/06/28 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/28 06:00
AID - 10.1177/1010428317703819 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317703819. doi: 10.1177/1010428317703819.